Last updated on November 2018

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Brief description of study

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Clinical Study Identifier: NCT02663908

Contact Investigators or Research Sites near you

Start Over

Global Clinical Compliance

Erlanger Health System
Chattanooga, TN United States
  Connect »